Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

This study has been terminated.

( Due to declining numbers of patients with unsuppressed viremia, Gilead combined the studies GS-US-183-0144 and 0145 into one study (GS-US-183-0145). )

Study NCT00707733 Information provided by Gilead Sciences

First Received: June 27, 2008 Last Updated: June 6, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given